Results 101 to 110 of about 72,428 (200)

Head‐to‐head comparison of TKI and CPI first‐line treatment strategies in advanced renal cell carcinoma—Real‐world data from the German research platform CARAT

open access: yesInternational Journal of Cancer, EarlyView.
What's New? The current standard of care for locally advanced or metastatic renal cell carcinoma (aRCC) is either a combination of two immune checkpoint inhibitors (CPI) or a CPI plus a tyrosine kinase inhibitor (TKI). Here, the authors simulate a head‐to‐head trial comparing the real‐world effectiveness of these combination therapies with TKI ...
Peter J. Goebell   +15 more
wiley   +1 more source

Multiple Roles of Autophagy in the Sorafenib Resistance of Hepatocellular Carcinoma

open access: yesCellular Physiology and Biochemistry, 2017
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide, and prognosis remains unsatisfactory since the disease is often diagnosed at the advanced stages.
Ting Sun, Hongchun Liu, Liang Ming
doaj   +1 more source

Clinical validation of a DNA methylation biomarker associated with overall survival of relapsed ovarian cancer patients

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Most patients with ovarian cancer (OC) relapse after first‐line chemotherapy, and prognosis with second‐line treatment depends largely on the platinum‐free interval. However, reliable biomarkers to predict response to second‐line therapy remain lacking.
Muhammad Habiburrahman   +7 more
wiley   +1 more source

TBCancer: A database for exploring characteristics and functions of tissue‐biased genes in cancer

open access: yesiMetaOmics, EarlyView.
This study defined 10,921 tissue‐biased genes across 54 normal tissues and 41 cancer types. Tumor‐associated tissue‐biased genes exhibit downregulation, mutations, and epigenetic modifications, correlating with poor clinical outcomes. Their inactivation promotes tumorigenesis by enhancing stemness and immune evasion, highlighting their value as ...
Zhuobin Lin   +7 more
wiley   +1 more source

Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.

open access: yesJournal of Hepatology, 2021
A. Cheng   +18 more
semanticscholar   +1 more source

Emerging Role of MRI‐Based Artificial Intelligence in Individualized Treatment Strategies for Hepatocellular Carcinoma: A Narrative Review

open access: yesJournal of Magnetic Resonance Imaging, EarlyView.
ABSTRACT Hepatocellular carcinoma (HCC) is the most common subtype of primary liver cancer, with significant variability in patient outcomes even within the same stage according to the Barcelona Clinic Liver Cancer staging system. Accurately predicting patient prognosis and potential treatment response prior to therapy initiation is crucial for ...
Feng Che   +5 more
wiley   +1 more source

Peri‐implant hypoxia as a potential barrier against ferroptotic mechanisms during peri‐implant diseases: A cross‐sectional study

open access: yesJournal of Periodontology, EarlyView.
Abstract Background Hypoxia modulates inflammation and oxidative stress through hypoxia‐inducible factor‐1α (HIF‐1α). Ferroptosis, an iron‐dependent cell death process, is regulated by glutathione peroxidase‐4 (GPX4) and involves lipid peroxidation markers like malondialdehyde (MDA).
Büşra Yılmaz   +5 more
wiley   +1 more source

Phase IIb Trial for the Palliative Treatment of Patients With Primary Hepatic Malignancy Unable to Receive Curative Treatment: Efficacy of Colchicine

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT This trial was to evaluate the efficacy and the safety of colchicine for the palliative treatment of patients with primary hepatic malignancy unable to receive curative treatment. Forty hepatocellular carcinoma (HCC) patients and two intrahepatic cholangiocarcinoma (ICC) patients signed the informed consents.
Zu‐Yau Lin   +8 more
wiley   +1 more source

Exploring the Potential Anticancer Effects of Lobelia chinensis Lour in Liver Cancer via Multiomics Analysis

open access: yesMed Research, EarlyView.
The incidence and mortality of liver cancer remain consistently high worldwide, with China particularly affected. To identify potential therapeutic components and elucidate their mechanisms of action, this study performed a comprehensive multiomics analysis based on the active ingredients of LCL.
Zixuan Yang   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy